GLP-1s and Peptides in Functional Medicine: Supply and Compliance Guide
Functional medicine practices are increasingly combining GLP-1 therapy with research peptides like BPC-157, NAD+, and sermorelin. This guide covers supply chain, compliance separation, and how to access both through one portal.
GLP-1s and Peptides in Functional Medicine: Supply and Compliance Guide
Functional medicine and integrative health practices are at the forefront of combining GLP-1 therapy with broader metabolic and longevity protocols. The combination of semaglutide or tirzepatide with peptides like BPC-157, NAD+, and sermorelin is increasingly common in high-end functional medicine practices.
But the supply chain and compliance requirements for these different product categories are distinct. Here is what functional medicine practitioners need to understand.
The Two Compliance Frameworks
Compounded GLP-1s (503A) are prescription medications prepared by a licensed compounding pharmacy on a patient-specific basis. They require:
- A valid patient-specific prescription
- A licensed prescriber with a valid NPI
- Documentation of medical necessity
Research peptides (RUO) are designated for research use only. They are not FDA-approved medications and are not intended for therapeutic use. They require:
- A separate ordering pathway from compounded medications
- Clear documentation that they are for research purposes
- Compliance with all applicable federal and state regulations
These two categories must be kept clearly separate in your practice — separate ordering, separate documentation, separate labeling.
The NAD+ Middle Ground
NAD+ occupies an interesting middle ground. 503A compounded NAD+ subcutaneous injection is available as a compounded medication through licensed 503A pharmacies — this is a prescription product with a valid compounding basis. It is distinct from NAD+ supplements or IV infusions, which have different regulatory frameworks.
For functional medicine practices, 503A compounded NAD+ sub-q injection is the most compliance-clear pathway for injectable NAD+ therapy.
Popular Functional Medicine Protocols
Functional medicine practices commonly combine:
- GLP-1 + NAD+: Metabolic optimization and cellular energy support
- GLP-1 + BPC-157: Weight management with tissue repair support (BPC-157 is RUO)
- GLP-1 + Sermorelin: Weight management with growth hormone axis support (Sermorelin is RUO)
- GLP-1 + CJC-1295/Ipamorelin: Metabolic and body composition protocols (RUO)
Each of these combinations requires clear compliance separation between the 503A compounded GLP-1 and the RUO peptide components.
Accessing Both Through MedClinic Partners
MedClinic Partners provides access to both 503A compounded GLP-1s and RUO research peptides through the same NPI-verified portal. The two product categories are clearly separated in your account — different ordering flows, different documentation, different labeling.
Apply for portal access — NPI verified in 60 seconds, no portal fees.
Related reading: GLP-1 Supply for Functional Medicine · Peptide Catalog · 503A vs 503B Explained
Explore Topics
Written by
Ian J.
Co-Founder & Managing Partner — Mass-Tort Pharma Background & Medical Operator
Ian is a co-founder of MedClinic Partners with over a decade of experience in mass-tort pharmaceutical matters and medical practice operations. He has personally overseen the launch and compliance infrastructure of multiple GLP-1 and peptide programs, and brings a unique legal-operational perspective to compounding supply chain management.
Editorial standards: All content on medclinicpartners.com is reviewed by licensed medical operators and compounding compliance specialists before publication. Articles are updated when regulatory guidance changes. This content is for licensed healthcare providers only and does not constitute medical advice.
